Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3152 for prevention of COVID-19 in healthy Japanese adults
jRCT2071230040Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sipavibart in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by AstraZeneca. Started Jul 2023; status: completed.
02
Drugs
sipavibart
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071230040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230040.